Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DEXCOM INC Director's Dealing 2022

May 23, 2022

30198_dirs_2022-05-23_0dcc8988-c46b-4c41-be99-52f4267466d5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2022-05-20

Reporting Person: Heller Bridgette P (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-05-20 Common Stock A 988 $0.001 Acquired 5355 Direct

Footnotes

F1: The RSU Award was granted on May 20, 2022 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.

F2: Included in this number are 2,000 unvested restricted stock units, 988 of which were granted on May 20, 2022 and shall vest on the earlier of the one year anniversary of the grant or the date of DexCom Inc's 2023 Annual Meeting and 1,012 of which were granted on September 13, 2019 and shall vest through September 13, 2022.